Drugs Made In America Acquisition Corp.
DMAA
$10.27
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 131.90K | 330.90K | 279.90K | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 131.90K | 330.90K | 279.90K | -- | |
| Operating Income | -131.90K | -330.90K | -279.90K | -- | |
| Income Before Tax | 2.29M | 1.25M | -279.90K | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 2.29M | 1.25M | -279.90K | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 2.29M | 1.25M | -279.90K | -- | |
| EBIT | -131.90K | -330.90K | -279.90K | -- | |
| EBITDA | -- | -- | -- | -- | |
| EPS Basic | 0.07 | 0.05 | -0.03 | 0.00 | |
| Normalized Basic EPS | 0.04 | 0.03 | -0.02 | -- | |
| EPS Diluted | 0.07 | 0.05 | -0.03 | 0.00 | |
| Normalized Diluted EPS | 0.04 | 0.03 | -0.02 | -- | |
| Average Basic Shares Outstanding | 33.52M | 24.79M | 8.57M | -- | |
| Average Diluted Shares Outstanding | 33.52M | 25.51M | 8.57M | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |